2-Amino-6-fluoro-N- [5-fluoro-pyridin-3-yl] pyrazolo [1,5-a] pyrimidin-3-carboxamide compound useful as an ATR kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof

• 收藏
• 分享

专利权人:

Vertex Pharmaceuticals Inc.

发明人:

CHARRIER, Jean-Damien,DAVIS, Christopher,FRAYSSE, Damien,ETXEBARRIA I JARDI, Gorka,PEGG, Simon,PIERARD, Francoise,PINDER, Joanne,STUDLEY, John,ZWICKER, Carl,SANGHVI, Tapan,WALDO, Michael,MEDEK, Ales,S

申请号：

ES14815187

公开号：

ES2768678T3

申请日:

2014.12.05

申请国别(地区):

ES

年份:

2020

代理人:

摘要：

A compound of Formula IB: ** Formula ** or a pharmaceutically acceptable salt thereof, wherein: Y1, Y2, Y3, Y4, Y5, Y6, Y7, Y8, Y9, Y10, Y11, Y12, Y13, Y14 , Y15, Y16, Y17, Y18 and Y19 are independently hydrogen or deuterium； provided that at least one of Y1, Y2, Y3, Y4, Y5, Y6, Y7, Y8, Y9, Y10, Y11, Y12, Y13, Y14, Y15, Y16, Y17, Y18 and Y19 is deuterium； each of X1, X2, X4, X5, X6, X7, X8 and X9 is independently 12C or 13C； X3 is independently -12C (O) - or -13C (O) -； and where a) Y12, Y13, Y14, Y15, Y16, Y17, Y18 and Y19 are deuterium, and Y1, Y2, Y3, Y4, Y5, Y6, Y7, Y8, Y9, Y10 and Y11 are independently hydrogen or deuterium； b) Y12, Y13, Y14, Y15, Y16, Y17, Y18 and Y19 are deuterium, and Y1, Y2, Y3, Y4, Y5, Y6, Y7, Y8, Y9, Y10, and Y11 are hydrogen； optionally where: i) X1, X2, X4, X5, X6, X7, X8 and X9 are 12C； and X3 is -12C (O) -； or where: ii) X1, X4, X5, X6, X7, X8 and X9 are 12C； X3 is -13C (O) -； and X2 is 13C； c) Y11, Y12, Y13, Y14, Y15, Y16, Y17, Y18 and Y19 are deuterium, and Y1, Y2, Y3, Y4, Y5, Y6, Y7, Y8, Y9 and Y10 are independently hydrogen or deuterium； optionally where Y11, Y12, Y13, Y14, Y15, Y16, Y17, Y18 and Y19 are deuterium, and Y1, Y2, Y3, Y4, Y5, Y6, Y7, Y8, Y9 and Y10 are hydrogen. d) where Y2, Y12, Y13, Y14, Y15, Y16, Y17, Y18 and Y19 are deuterium, and Y1, Y3, Y4, Y5, Y6, Y7, Y8, Y9, Y10 and Y11 are independently hydrogen or deuterium； optionally where Y2, Y12, Y13, Y14, Y15, Y16, Y17, Y18 and Y19 are deuterium, and Y1, Y3, Y4, Y5, Y6, Y7, Y8, Y9, Y10, and Y11 are hydrogen； e) Y12, Y13, Y18 and Y19 are deuterium, and Y1, Y2, Y3, Y4, Y5, Y6, Y7, Y8, Y9, Y10, Y11, Y14, Y15, Y16 and Y17 are hydrogen or deuterium； optionally where Y12, Y13, Y18 and Y19 are deuterium, and Y1, Y2, Y3, Y4, Y5, Y6, Y7, Y8, Y9, Y10, Y11, Y14, Y15, Y16 and Y17 are hydrogen. f) where Y3, Y4, Y5, Y6, Y7, Y8, Y9, Y10 and Y11 are deuterium, and Y1, Y2, Y12, Y13, Y14, Y15, Y16, Y17, Y18 and Y19 are independently deuterium or hydrogen； optionally where Y3, Y4, Y5, Y6,

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/